lysergic acid diethylamide has been researched along with Depressive Disorder, Major in 9 studies
Lysergic Acid Diethylamide: Semisynthetic derivative of ergot (Claviceps purpurea). It has complex effects on serotonergic systems including antagonism at some peripheral serotonin receptors, both agonist and antagonist actions at central nervous system serotonin receptors, and possibly effects on serotonin turnover. It is a potent hallucinogen, but the mechanisms of that effect are not well understood.
lysergic acid diethylamide : An ergoline alkaloid arising from formal condensation of lysergic acid with diethylamine.
Depressive Disorder, Major: Disorder in which five (or more) of the following symptoms have been present during the same 2-week period and represent a change from previous functioning; at least one of the symptoms is either (1) depressed mood or (2) loss of interest or pleasure. Symptoms include: depressed mood most of the day, nearly every daily; markedly diminished interest or pleasure in activities most of the day, nearly every day; significant weight loss when not dieting or weight gain; Insomnia or hypersomnia nearly every day; psychomotor agitation or retardation nearly every day; fatigue or loss of energy nearly every day; feelings of worthlessness or excessive or inappropriate guilt; diminished ability to think or concentrate, or indecisiveness, nearly every day; or recurrent thoughts of death, recurrent suicidal ideation without a specific plan, or a suicide attempt. (DSM-5)
Excerpt | Relevance | Reference |
---|---|---|
"Our search revealed 12 eligible studies (n = 257; 124 healthy participants, and 133 patients with mood disorders), with data from randomized controlled trials involving psilocybin (n = 8), lysergic acid diethylamide ([LSD]; n = 3), and ayahuasca (n = 1)." | 5.12 | Classic serotonergic psychedelics for mood and depressive symptoms: a meta-analysis of mood disorder patients and healthy participants. ( de Manincor, M; Galvão-Coelho, NL; Gonzalez, M; Marx, W; Perkins, D; Sarris, J; Sinclair, J, 2021) |
"Psychedelic therapy shows promise for Major Depressive Disorder, especially when treatment-resistant, as well as life-threatening illness distress." | 3.01 | Psychedelic therapy for depressive symptoms: A systematic review and meta-analysis. ( Cleare, AJ; Ko, K; Kopra, EI; Rucker, JJ, 2023) |
"Chronic pain is a leading cause of disability, reduced productivity, healthcare seeking behavior, and a contributor to opioid overdose in the United States." | 3.01 | Are psychedelic medicines the reset for chronic pain? Preliminary findings and research needs. ( Baumann, MH; Belouin, SJ; Berger, A; Dworkin, RH; Ghauri, MH; Hendricks, PS; Henningfield, JE; Lanier, RK; Ross, S; Zia, FZ, 2023) |
"Recent trials with psychedelics in major depressive disorder and treatment-resistant depression showed remarkable improvements in depressive symptoms that can last for up to several months after even a single administration." | 1.72 | How to account for hallucinations in the interpretation of the antidepressant effects of psychedelics: a translational framework. ( Hillhouse, TM; Magaraggia, I; Porter, JH; Schreiber, R; van den Berg, M, 2022) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 1 (11.11) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (11.11) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 7 (77.78) | 2.80 |
Authors | Studies |
---|---|
Han, B | 1 |
Blanco, C | 1 |
Einstein, EB | 1 |
Compton, WM | 1 |
van den Berg, M | 1 |
Magaraggia, I | 1 |
Schreiber, R | 1 |
Hillhouse, TM | 1 |
Porter, JH | 1 |
Yang, KH | 1 |
Han, BH | 1 |
Palamar, JJ | 1 |
Ko, K | 1 |
Kopra, EI | 1 |
Cleare, AJ | 1 |
Rucker, JJ | 1 |
Zia, FZ | 1 |
Baumann, MH | 1 |
Belouin, SJ | 1 |
Dworkin, RH | 1 |
Ghauri, MH | 1 |
Hendricks, PS | 1 |
Henningfield, JE | 1 |
Lanier, RK | 1 |
Ross, S | 1 |
Berger, A | 1 |
Galvão-Coelho, NL | 1 |
Marx, W | 1 |
Gonzalez, M | 1 |
Sinclair, J | 1 |
de Manincor, M | 1 |
Perkins, D | 1 |
Sarris, J | 1 |
Schmid, Y | 1 |
Gasser, P | 1 |
Oehen, P | 1 |
Liechti, ME | 1 |
El Khoury, A | 1 |
Johnson, L | 1 |
Aberg-Wistedt, A | 1 |
Stain-Malmgren, R | 1 |
Shagass, C | 1 |
Straumanis, JJ | 1 |
4 reviews available for lysergic acid diethylamide and Depressive Disorder, Major
Article | Year |
---|---|
Psychedelic therapy for depressive symptoms: A systematic review and meta-analysis.
Topics: Depression; Depressive Disorder, Major; Hallucinogens; Humans; Lysergic Acid Diethylamide; Psilocybi | 2023 |
Are psychedelic medicines the reset for chronic pain? Preliminary findings and research needs.
Topics: Chronic Pain; Depressive Disorder, Major; Hallucinogens; Humans; Lysergic Acid Diethylamide; Psilocy | 2023 |
Classic serotonergic psychedelics for mood and depressive symptoms: a meta-analysis of mood disorder patients and healthy participants.
Topics: Affect; Banisteriopsis; Depression; Depressive Disorder, Major; Double-Blind Method; Hallucinogens; | 2021 |
Evoked potentials and psychopathology.
Topics: Adjustment Disorders; Age Factors; Attention; Auditory Cortex; Bipolar Disorder; Brain Diseases; Com | 1969 |
5 other studies available for lysergic acid diethylamide and Depressive Disorder, Major
Article | Year |
---|---|
Mental health conditions and receipt of mental health care by illicit lysergic acid diethylamide (LSD) use status among young adults in the United States.
Topics: Adolescent; Adult; Cross-Sectional Studies; Depressive Disorder, Major; Humans; Lysergic Acid Diethy | 2022 |
How to account for hallucinations in the interpretation of the antidepressant effects of psychedelics: a translational framework.
Topics: Antidepressive Agents; Depressive Disorder, Major; Hallucinations; Hallucinogens; Humans; Lysergic A | 2022 |
Past-year hallucinogen use in relation to psychological distress, depression, and suicidality among US adults.
Topics: Adult; Depression; Depressive Disorder, Major; Hallucinogens; Humans; Lysergic Acid Diethylamide; N- | 2022 |
Acute subjective effects in LSD- and MDMA-assisted psychotherapy.
Topics: Adult; Combined Modality Therapy; Compassionate Use Trials; Consciousness Disorders; Depressive Diso | 2021 |
Effects of long-term lithium treatment on monoaminergic functions in major depression.
Topics: Adult; Aged; Bipolar Disorder; Blood Platelets; Carrier Proteins; Depressive Disorder, Major; Female | 2001 |